Search Results
Jul 22, 2026, 08:30 ET Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
FXI-inhibition approach for thromboembolic diseases. Building on these findings, we have initiated the ORBIT-XI program (Optimizing RNA-Based Inhibition of Thrombosis), including several Phase 2b trials designed to support rapid progression into Phase 3 development across multiple indications."
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 22, 2026, 08:30 ET NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable
More news about: NeuroSense
Jul 22, 2026, 08:22 ET Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
FXI-inhibition approach for thromboembolic diseases. Building on these findings, we have initiated the ORBIT-XI program (Optimizing RNA-Based Inhibition of Thrombosis), including several Phase 2b trials designed to support rapid progression into Phase 3 development across multiple indications."
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 22, 2026, 07:24 ET 瑞博生物披露全球首個靶向FXI的siRNA藥物vortosiran的IIa期臨床積極數據
一直是心血管醫學領域長期以來夢寐以求的『醫學聖盃』。本次IIa期臨床數據進一步夯實了我們的堅定信念，即對於血栓栓塞性疾病而言，vortosiran是一種安全且具有顯著差異化優勢的FXI抑制療法。基於這些研究結果，我們已啟動了一個包含多項IIb期試驗在內的ORBIT-XI (Optimizing RNA-Based Inhibition of Thrombosis) 戰略開發計劃，旨在推動vortosiran快速進入涵蓋多種適應症的III期臨床開發。我們期待vortosiran在下一步研究中的優異表現，爭取早日為全球患者帶來更優的治療選擇。」關於vortosiran
More news about: 蘇州瑞博生物技術股份有限公司
Jul 21, 2026, 16:30 ET Ascidian Therapeutics Announces Leadership Transition
process."Ascidian was built around a bold idea: that RNA editing could unlock new possibilities for patients with serious genetic diseases," said Michael Ehlers, M.D., Ph.D., Chair of the Board. "Today, we have a first-in-class RNA exon editing platform and a clear path forward. It has been
More news about: Ascidian Therapeutics
Jul 21, 2026, 08:30 ET AllerGene AI Therapeutics Founder and CEO Sid Kerkar to Present In Vivo Mast Cell-Targeting CAR Technology at Hanson Wade Summit
allergic asthma, food allergies, and anaphylaxis are treated."Integrating Cell Therapy, RNA Delivery, and Mast Cell BiologyAllerGene's platform integrates advances in cell therapy, RNA delivery, and the biology of allergic diseases to engineer immune cells directly in the body using
More news about: AllerGene AI Therapeutics
Jul 21, 2026, 08:30 ET Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
precocious puberty.The analysis used weighted gene expression signatures in ER-positive MCF7 cells and integrated published phosphoproteomic and RNA-seq datasets to assess modulation of PKC-β and AKT signaling pathways.The analysis identified a shared estrogen-responsive gene network and
More news about: Atossa Therapeutics Inc
Jul 20, 2026, 17:58 ET Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
accordance with Nasdaq Listing Rule 5635(c)(4).About Atrium TherapeuticsAtrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary
More news about: Atrium Therapeutics
Jul 20, 2026, 10:00 ET Akagera Medicines Reports Positive First-in-Human Data for Single-Ascending-Dose of AKG-100, Advancing a Potentially Transformative Long-Acting Therapeutic for Drug-Resistant Tuberculosis
multidrug regimens.About Akagera MedicinesAkagera Medicines, Inc. is a clinical-stage biopharmaceutical company developing messenger-RNA and lipid-nanoparticle therapeutics and vaccines for infectious diseases that disproportionately affect the Global South, including tuberculosis, nontuberculous
More news about: Akagera Medicines Inc
Jul 20, 2026, 09:00 ET Argo Biopharma Doses First Participant in Phase I Clinical Trial of Factor XI Targeting siRNA Therapy BW-41012
July 20, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced the first participant has been dosed in its Phase I study of BW-41012, an investigational siRNA therapy
More news about: Argo Biopharmaceutical Co., Ltd
Jul 20, 2026, 08:08 ET FAST Awards Grant to Nobel Laureate Frances Arnold to Advance Next-Generation Tools for a Novel Therapeutic Strategy for Angelman Syndrome
the translational utility of these new building blocks within RNA therapeutics for Angelman syndrome."Nucleoside analogs are synthetic molecules designed to resist breakdown in the body, a property that may be useful in developing RNA therapeutics with improved durability. However, nucleoside analogs
More news about: AS2Bio
Jul 16, 2026, 10:31 ET Complement 3 Glomerulopathy Market Set for Transformation: 4 Emerging Therapies Leading the Next Growth Phase | DelveInsight
Emerging therapies targeting novel mechanisms such as dual complement inhibitors (C5 and Factor H (KP104), MASP-3 inhibitors (Zaltenibart), RNA interference (RNAi) therapeutics targeting complement C3 (ARO-C3), and others are showing promise as potential treatment options. The expected launch
More news about: DelveInsight Business Research, LLP
Jul 16, 2026, 10:30 ET Oligonucleotide Synthesis Market worth $32.72 billion by 2031 - Exclusive Report by MarketsandMarkets™
oligonucleotide-based drugs) segment accounted for the largest share of the market. ASOs are short, single-stranded nucleic acids that bind selectively to RNA targets. They have seen rapid clinical and commercial uptake owing to their versatility in modulating gene expression, treating rare genetic disorders,
More news about: MarketsandMarkets
Jul 16, 2026, 09:00 ET Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Jul 16, 2026, 07:30 ET Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
partnerships". Ronen Eavri, Co-founder & CEO of Barcode Nanotech, commented: "Barcode Nanotech has developed a library of novel lipids for RNA and DNA, LNP-based delivery, through a unique in vivo & AI-based screening platform which allow simultaneously screening of hundreds of different
More news about: Galmed Pharmaceuticals Ltd.
Jul 16, 2026, 07:00 ET Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.Headquartered in Bridgewater, New Jersey, Insmed has offices and
More news about: Insmed Incorporated
Jul 16, 2026, 04:18 ET Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich
Grünenthal has built strategic in-house capabilities to advance oligonucleotide modalities, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA), as potential therapeutic approaches for pain and related neurological indications.One of Grünenthal's key objectives for the collaboration
More news about: Grünenthal Group
Jul 15, 2026, 09:00 ET Primrose Bio Awarded NIH Grant to Develop Genetic Medicine Drug Design Technology
$2 million grant builds on research to develop sequence elements that improve DNA- and RNA-based medicine efficacySAN DIEGO, July 15, 2026 /PRNewswire/ -- Primrose Bio, Inc., a company with proprietary
More news about: Primrose Bio
Jul 15, 2026, 08:47 ET Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS
TherapeuticsRactigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™,
More news about: Ractigen Therapeutics
Jul 15, 2026, 05:56 ET Skyhawk Therapeutics gibt die Ausweitung seiner globalen zulassungsrelevanten klinischen Studie „FALCON-HD" für SKY-0515 zur Behandlung der Huntington-Krankheit auf die Vereinigten Staaten, Kanada und das Vereinigte Königreich bekannt
Skyhawk Therapeutics, Inc., ein Biotechnologieunternehmen im klinischen Stadium, das neuartige kleinmolekulare Therapien zur Modulation von RNA-Zielstrukturen entwickelt, gibt bekannt, dass es weitere behördliche Genehmigungen für den Start seiner Phase-2/3-Schlüsselstudie FALCON-HD (004-ANZ
More news about: Skyhawk Therapeutics
Jul 14, 2026, 16:30 ET Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
(GEP) test designed to guide systemic treatment decisions for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD). Using RNA expression data from lesional skin scraping samples—no biopsy required—the test evaluates 487 genes across 12 inflammatory and cutaneous biology pathways
More news about: Castle Biosciences, Inc.
Jul 14, 2026, 10:57 ET Renew Labs Receives Accreditation from the College of American Pathologists
assay development, and clinical laboratory programs, with specialized expertise in long-read and native-read sequencing, including methylation analysis, RNA characterization, and complex genomic regions. The CAP accreditation further strengthens Renew's ability to support partners across research, clinical
More news about: Renew Biotechnologies
Jul 14, 2026, 08:36 ET Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces it has received additional regulatory approvals to open its Phase 2/3 FALCON-HD (004-ANZ and 004-WW) pivotal trial, with an IND acceptance
More news about: Skyhawk Therapeutics
Jul 14, 2026, 08:17 ET Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces it has received additional regulatory approvals to open its Phase 2/3 FALCON-HD (004-ANZ and 004-WW) pivotal trial, with an IND acceptance
More news about: Skyhawk Therapeutics
Jul 14, 2026, 06:30 ET Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
candidate, is a potentially disease-modifying treatment for PRKAG2 syndrome. Using Atrium's precision RNA delivery technology, ATR 1072 uses small interfering RNA (siRNA) to silence mutant PRKAG2 messenger RNA (mRNA), normalize AMP-activated protein kinase (AMPK) activity and reduce pathogenic glycogen accumulation,
More news about: Atrium Therapeutics